Cost-effectiveness of vortioxetineversusvenlafaxine (extended release) in the treatment of major depressive disorder in South Korea

Abstract

Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy.

Considering the societal perspective in economic evaluations: a systematic review in the case of depression

“…Three studies analysed data from Sweden [ 55 , 56 , 59 ] and another two from India [ 58 , 77 ]. The remaining six studies used data from Japan [ 65 ], Greece [ 53 ], Canada [ 74 ], Belgium [ 26 ], Korea [ 34 ] and Finland [ 70 ].…”

“…Concerning the perspective, 22 of the studies (42%) applied the societal perspective [ 30 , 38 , 40 – 43 , 45 , 48 , 49 , 53 – 57 , 59 , 63 , 66 , 67 , 69 , 71 – 73 , 76 ]. Eighteen studies conducted an evaluation considering both positions [ 26 – 29 , 31 , 32 , 34 , 37 , 39 , 50 , 51 , 58 , 62 , 64 , 65 , 74 , 75 , 77 ] and 12 focused on the healthcare perspective and calculated societal costs separately [ 33 , 35 , 36 , 44 , 46 , 47 , 52 , 60 , 61 , 65 , 70 , 78 ]. One study did not explain which perspective was used [ 68 ].…”

“…Considering the intervention type, 26% of the studies compared two or more different pharmaceuticals [ 26 , 28 , 34 , 36 , 38 , 53 , 55 – 57 , 59 , 62 , 66 , 69 , 70 ], whereby the main part of the articles evaluated non-pharmaceutical interventions such as cognitive behavioural therapy or other psycho-educational therapies. Collaborative care interventions were evaluated in eight studies [ 27 , 40 , 42 – 44 , 49 , 60 , 72 ] and seven articles focused on a combination of pharmaceutical and psychological interventions [ 46 , 50 , 54 , 58 , 65 , 67 , 75 ].…”

Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder

“…Although vortioxetine did not dominate in the base case of this study versus venlafaxine XR (which has been on the Chinese market since 2000), vortioxetine consistently dominated versus branded venlafaxine XR across region sensitivity analyses. In previous economic evaluations, vortioxetine has shown dominance versus venlafaxine XR in South Korea 42 , versus duloxetine in Norway 43 , and as a second-line therapy (versus agomelatine, bupropion, venlafaxine and sertraline) in Finland 44 . It should be noted that the cost-effectiveness model applied in this study was based on units of STPs rather than health-economic standard effect measures such as quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) 45 .…”

Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom

“…The results based onMontgomery et al (2014), demonstrated that vortioxetine had a 98% probability of being cost-effective versus agomelatine at a threshold of £20,000/QALY. These results are considered particularly robust as they are based on data from a head-to-head study.This economic model has been adapted from a previously published model conducted in switch patients in Finland and an overall MDD population in South Korea (44) (45). In the Finnish analyses Vortioxetine was found to be a dominant treatment option versus agomelatine, sertraline and venlafaxine.…”